Recombinant myxoma virus‐derived immune modulator m‐t7 accelerates cutaneous wound healing and improves tissue remodeling

Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age. New approaches to accelerate and improve, or “fine tune” the healing process, so as to improve the quality of cutaneous wound healing and management, are the focus of intense investigation. Here, we investigate the topical application of a recombinant immune modulating protein which inhibits the interactions of chemokines with glycosaminoglycans, reducing damaging or excess inflammation responses in a splinted full‐thickness excisional wound model in mice. M‐T7 is a 37 kDa‐secreted, virus‐derived glycoprotein that has demonstrated therapeutic efficacy in numerous animal models of inflammatory immunopathology. Topical treatment with recombinant M‐T7 significantly accelerated wound healing when compared to saline treatment alone. Healed wounds exhibited properties of improved tissue remodeling, as determined by collagen maturation. M‐T7 treatment accelerated the rate of peri‐wound angiogenesis in the healing wounds with increased levels of TNF, VEGF and CD31. The immune cell response after M‐T7 treatment was associated with a retention of CCL2 levels, and increased abundances of arginase‐1‐expressing M2 macrophages and CD4 T cells. Thus, topical treatment with recombinant M‐T7 promotes a pro‐resolution environment in healing wounds, and has potential as a novel treatment approach for cutaneous tissue repair.